We have anecdotally noted that serum LDH values rise after the infusion of autologous peripheral blood progenitor cells (PBPCs), presumably the result of cellular lysis. To further study this issue, we retrospectively reviewed 203 consecutive patients undergoing autologous PBPC transplant from August 1996 to December 1997. 194 patients were evaluable, having documented LDH values on day ؊1 to day +5 post-transplant. All patients received cytokine mobilization for PBPC collection, and 99% received a chemotherapy-only preparative regimen. 99% of patients had a rise in serum LDH after PBPC infusion. 76% had a normal LDH prior to PBPC infusion that became abnormally high after infusion; 22% began with an abnormally high value that became higher with the infusion of PBPCs. The LDH rose at least 50% in 91% of patients. 92% of the patients had their peak LDH value occur on day +1 post-transplant. The total dose of CD34 + cells infused negatively correlated with peak percentage change of LDH (P = 0.0007). This result was initially perplexing, as we believed that a higher number of infused cells would correlate with a higher LDH value as a result of in vivo cellular lysis. However, the total number of CD34 + cells also negatively correlated with the number of phereses required to collect our threshold of 2.0 × 10 6
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We have observed that serum LDH values in patients undergoing autologous peripheral blood progenitor cell (PBPC) transplantation frequently rise after the infusion of PBPCs. This is generally of little clinical consequence. We believed this LDH rise was related to in vivo cellular lysis, and we theorized that it might be related to increasing numbers of CD34 + cells infused. We elected to examine the frequency of LDH elevation after autologous PBPC transplantation and analyze variables that might be associated with this LDH elevation.
Materials and methods

Patient characteristics
We retrospectively studied 203 consecutive adult patients undergoing autologous PBPC transplant from August 1996 to December 1997. 194 patients had documented LDH values during this study period and were therefore evaluable. LDH values were analyzed from day Ϫ1 to day +5 post-transplant. Patient characteristics are shown in Table 1 .
PBPC collection and processing
All patients received cytokine priming for PBPC collection. Most patients received G-CSF (filgrastim) 5-10 g/kg/day administered subcutaneously for 8-10 days with PBPC collection beginning on day +5. The total yield of PBPC collection was at least 2.0 × 10 6 CD34 + cells per kg. Patients were harvested on a COBE Spectra leukopheresis machine (COBE, Denver, CO, USA).
Transplant protocol
Ninety-nine percent of patients received a chemotherapyonly preparative regimen. The majority of lymphoma patients received busulfan, cyclophosphamide, VP-16: (busulfan 14 mg/kg, etoposide 60 mg/kg, cyclophosphamide 120 mg/kg); the majority of breast cancer patients received cyclosphosphamide, thiotepa, carboplatin 
Supportive care
Patients received prophylactic antibiotics consisting of oral acyclovir and ciprofloxacin. Patients who had persistent fevers had their antibiotic cover broadened. Patients received red blood cell transfusions to maintain a hemoglobin of greater than 9 g/dl, and platelet transfusions were given for platelet counts less than 10 × 10 9 /l.
LDH evaluation
All patients had a serum LDH level drawn daily from day Ϫ1 to day +5 post-transplant. The institutional LDH reference interval is 110 to 220 U/l.
Statistical analysis
Univariate analysis of peak percentage change of LDH included Spearman correlations for continuous factors and a Wilcoxon rank sum or Kruskal Wallis test for categorical data. The regression analysis of peak percentage change of LDH was performed on a 'trimmed' variable where three extreme values (685, 1262, 1389) were set to 600. Total CD34 + cell dose was included in the multiple regression model and all other variables were tested in a stepwise process. P values of 0.05 or less were considered to be statistically significant.
Results
A rise in LDH after the infusion of autologous PBPCs was experienced by 99% of patients. 76% had a normal LDH that become abnormally high; 22% had an abnormally high LDH on day 0 that became higher after the infusion of autologous stem cells. 91% of patients experienced at least a 50% increase of serum LDH. The absolute LDH values by transplant day are shown in Table 2 , and graphically in Figure 1 .
A univariate analysis was performed to determine factors related to the peak percentage change of LDH. Variables tested included age, remission status, gender, CD34 + cell dose, prior radiation therapy, number of courses or prior chemotherapy, and diagnosis (lymphoma vs breast cancer vs other). There was a strong negative correlation of the number of CD34
+ cells with peak percentage change of LDH (P = 0.0007). This result was initially perplexing, as we had postulated that more progenitor cells infused might result in more in vivo cellular lysis, contributing to a higher LDH.
We then examined variables that were associated with CD34 + cell yield. One variable tested was the number of phereses required to collect our threshold target of 2.0 × 10 6 CD34
+ cells per kg. Patients having low yields of CD34 + cells during leukopheresis tended to require additional, repeated pheresis procedures to reach our threshold target of CD34 + cells. We found a strong negative correlation of the number of phereses with CD34
+ cell yield, shown graphically in Figure 2 .
We proceeded to include the number of phereses as a variable in a multivariate analysis with respect to the percentage changes in serum LDH after infusion of PBPCs. We found that the number of phereses highly correlate with peak percentage change of LDH (0.0001). Indeed, the number of phereses was the only variable of significance in the multivariate model. This was true even after adjusting for the total CD34 + cell dose.
Discussion
We initiated this study because we had anecdotally noted that many patients had a rise in their serum LDH after infusion of PBPCs. This study confirmed that LDH elevation is almost universal after infusion of PBPCs. The LDH elevation peaks on day +1, and generally increases at least two-fold. The etiology of the LDH elevation is, in broad terms, either an in vivo phenomenon, an ex vivo phenomenon, or a combination of both. That is, if one assumes that cellular lysis is the cause for LDH elevation, than this lysis either occurs predominantly in vivo after the infusion of autologous stem cells, or ex vivo during the collection, processing, freezing, and thawing of PBPCs. The fact that there was a negative correlation between total number of CD34 + cells infused and LDH elevation is evidence against an in vivo phenomenon. Multiple leukopheresis procedures are associated with increasing numbers of RBC collected with CD34 + nucleated WBCs. Such RBCs frequently hemolyse, releasing LDH. While we did not directly measure the LDH concentration in the collection bags holding the PBPCs, we hypothesized that, based on our correlation of LDH elevation with the number of pheresis procedures, LDH elevation is an ex vivo phenomenon. Thus, we feel it is likely that the LDH is literally being transfused into the patient at the time of PBPC infusion, which potentially explains the rapid LDH rise.
It was possible that other mechanisms may be contributing to this rise in LDH elevation. It is quite likely that some degree of in vivo cellular lysis/hemolysis occurs after PBPC infusion. It is also possible that non-specific causes of LDH rise, such as toxicity of the chemotherapy preparative regimen, or other phenomenon, may be contributing as well. However, the fact that the serum LDH reaches baseline values by day +4 post-transplant implies that the LDH elevation is a phenomenon that is directly related to the infusion of autologous stem cells.
There was little clinical consequence of the LDH elevation. Patients whose LDH rose more than others did not have a significantly different clinical course. Generally, the infusion of PBPCs is extremely well tolerated.
1 One series has postulated that possible toxicities, such as flushing and chills during stem cell infusion, may be related to DMSO, or other cryoprotectants infused. 2 Whether the volume of DMSO used with increasing numbers of pheresis procedures contributes to the rise in LDH elevation is conjectural at this point. However, more efficient mobilization strategies that yield larger numbers of PBPCs with fewer leukophereses might reduce the amount of cryoprotectant necessary, and might also reduce the LDH elevation described in this report.
